Sanajy S. Patel, Gayatri C. Patel, Chirag S. Patel
Sanajy S. Patel1*, Gayatri C. Patel2, Chirag S. Patel2
1Shri B. M. Shah College of Pharmaceutical Edu. and Research, Modasa, Gujarat, India.
2Ramanbhai Patel College of Pharmacy, Changa, Gujarat, India.
Volume - 15,
Issue - 3,
Year - 2023
The aim of the present study was to formulate stable silver sulfadiazine (SSD) liposomal gel suitable for topical delivery with a view to increase bactericidal activity in burn therapy. SSD liposomes were formulated using thin film hydration technique. A 23 factorial design was utilized to study the effect of the molar ratio of lipid: cholesterol (X1), drug concentration (X2) and hydration volume on Encapsulation efficiency (EE%) and vesicle size. Selected batch of liposome was incorporated in to PVPK-30 and HPMCK4M gel base to prepare the liposomal gel formulation, which was evaluated for in-vitro release and in-vivo study. It was evident from the derived polynomial equations and constructed contour plot, an increase in the level of X1 and a decrease in the X2 lead to an increase in EE% and increase in vesicle size. Each of the prepared liposomal gel formulation significantly improved (P<0.05) cumulative amount of drug release owing to the influence of the gel matrix. Among the liposomal gel formulation, L6 (prepared at high level of X1 and low level of X2) showed best release may be due to efficient hydration of the film and more total amount of drug entrapped. In-vivo studies revealed that a liposomal gel containing 0.5% SSD was more effective in wound healing compared to marketed cream.
Cite this article:
Sanajy S. Patel, Gayatri C. Patel, Chirag S. Patel. Development of Liposomal Encapsulated Silver Sulfadiazine Gel for Burn Therapy. Research Journal of Pharmaceutical Dosage Forms and Technology. .2023; 15(3):175-183. doi: 10.52711/0975-4377.2023.00029
Sanajy S. Patel, Gayatri C. Patel, Chirag S. Patel. Development of Liposomal Encapsulated Silver Sulfadiazine Gel for Burn Therapy. Research Journal of Pharmaceutical Dosage Forms and Technology. .2023; 15(3):175-183. doi: 10.52711/0975-4377.2023.00029 Available on: https://rjpdft.com/AbstractView.aspx?PID=2023-15-3-5
1. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn Wound Infections. Clin Microbiol Rev. 2006; 19(2):403–434.
2. Atiyeh BS, Costagliola M, Hayek SN, Dibo SA. Effect of silver on burn wound infection control and healing: review of the literature. Burns. 2007; 33:139–148.
3. Fox CL, Modak SM. Mechanism of silver sulfadiazine action on burn wound infections. Antimicrob Agents Chemother. 1974; 5:582–588.
4. Maple PAC, Hamilton-Miller JMT, Brranfltt W. Comparison of the in-vitro activities of the topical antimicrobials azelaic and, nitroforazone, silver sulphadiazine and mupirocin against methcillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1992; 29:661–668.
5. Mcdonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev. 1999; 12:147–179.
6. Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv. 2009; 27:76–83.
7. Bult A. Silver sulfadiazine and related antibacterial metal sulfanilamides: facts and fancy. Pharm Int. 1982; 3:400–404.
8. Capelli CC, Wis K. Inventor; Biointerface Technologies, Inc., Madison, Wis, assignee. Metal Based antimicrobial coating. United States Patent 4933178.1990 June 12.
9. Dollery C. Silver sulfadiazine. In: Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1999. p. S32–5.
10. Wilkinson LJ, White RJ, Chipman JK. Silver and nanoparticles of silver in wound dressings: a review of efficacy and safety. J Wound Care. 2011; 20(11):543-549.
11. White RJ, Cooper R. Silver sulphadiazine: A review of the evidence. Wounds UK. P. 51-61.
12. Margalit R, Okon M, Yerushalmi N, Avidor E. Bioadhesive liposomes as topical drug delivery systems: molecular and cellular studies. J Control Release. 1992; 19(1–3):275–287.
13. Xiaoming X, Mansoor AK, Diane JB. A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment, Int J Pharma. 2011; 419(1-2):52–59.
14. Mahawar Sheetal. Development and Characterization of Docetaxel Encapsulated pH-Sensitive Liposomes for Cancer Therapy. Research J. Pharma. Dosage Forms and Tech. 2013; 5(3): 151-160.